LIMA1

Across TCGA pan-cancer cohorts, LIMA1 mass-spec protein is linked to patient survival in 8 of 34 cancer types, making it a survival-associated LIMA1 data layer compared with 18 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher LIMA1 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated LIMA1 expression acts as an unfavorable survival marker, although some lineages such as PDAC and UCEC show a favorable association.

PDAC, UCEC, and COAD are the cancer types where LIMA1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Quartile	All	0.577	0.284	<.001	39	view →
UCEC	DFS	Tertile	All	1.000	0.824	.001	38	view →
COAD	DFS	Median	All	1.000	0.886	.020	30	view →
CCRCC	OS	Median	All	0.731	0.934	.002	11	view →
GBM	DFS	Median	All	0.289	0.443	.046	2	view →
HNSC	DFS	Quartile	III,IV	1.000	0.868	.020	2	view →
LUAD	OS	Median	All	0.980	0.781	.030	2	view →
LSCC	DFS	Median	All	0.627	0.916	.035	1	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

LIMA1–PDAC (DFS)

Open the PDAC breakdown →